AUREOGEN BIOSCIENCES

AureoGen Biosciences was incorporated on August 12, 2003. The company’s business is focused on the development of novel chemistry and genetic engineering methodologies for the modification of cyclic peptide-based compounds. Historically, structural modifications required to convert a native cyclic peptide into a functional drug often involved complicated and expensive synthetic chemistry approaches. This hampered the development of many promising drug candidates. It also prevented optimization... (such as reduction of side effects) of many existing drugs. AureoGen is taking advantage of recent advances in medicinal chemistry to develop novel approaches that allow efficient, cost-effective modification, optimization, and production of cyclic peptide compounds. AureoGen’s chemistries allow many modifications (to cyclic peptides) to be introduced directly, without the need for the multiple synthesis steps, disassembly of the core ring structure, and re-synthesis of large portions of the molecule, that characterized older approaches. Similarly, advances in biology and genetics have produced tools and knowledge that allow efficient structural modification of cyclic peptides by (genetic) engineering of the non-ribosomal peptide synthase (NRPS) complexes responsible for their synthesis in the producer organisms. Thus, using state-of-the-art chemical and genetic engineering methodologies, AureoGen is producing novel cyclic peptide-based drug candidates that are new chemical entities (NCEs) and that have the pharmacological properties required for development into useful therapeutics. AureoGen’s methodologies allow for the efficient and cost-effective in-depth exploration of the pharmacological properties (structure activity relationships, SAR) of virtually any cyclic peptide, as well as simple and economical generation of entirely novel cyclic peptides.More